Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Lowered by Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other brokerages also recently weighed in on KLRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Finally, Chardan Capital began coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.00.

Kalaris Therapeutics Price Performance

Shares of NASDAQ:KLRS opened at $9.82 on Friday. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $12.90. The stock has a market capitalization of $183.65 million, a price-to-earnings ratio of -2.60 and a beta of -0.13. The company’s 50 day simple moving average is $9.36 and its 200 day simple moving average is $6.97.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju acquired 479,847 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average price of $10.42 per share, with a total value of $5,000,005.74. Following the purchase, the director directly owned 1,979,847 shares in the company, valued at approximately $20,630,005.74. This trade represents a 31.99% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 74.99% of the stock is currently owned by insiders.

Institutional Trading of Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KLRS. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics during the third quarter worth $130,000. Walleye Capital LLC acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter valued at $95,000. XTX Topco Ltd acquired a new stake in shares of Kalaris Therapeutics during the 4th quarter valued at $92,000. Keel Point LLC bought a new stake in Kalaris Therapeutics during the 4th quarter worth $86,000. Finally, Johnson Financial Group Inc. bought a new stake in Kalaris Therapeutics during the 3rd quarter worth $58,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.